Le Lézard
Classified in: Health
Subjects: LAW, ATY

Authorized by the Ontario Superior Court of Justice - NOTICE OF INTENT TO DISCONTINUE PROPOSED ZIMMER BIOMET EXPLOR MODULAR RADIAL HEAD SYSTEM CLASS ACTION


THIS IS AN IMPORTANT NOTICE FOR ZIMMER BIOMET EXPLOR MODULAR RADIAL HEAD SYSTEM RECIPIENTS THAT MAY AFFECT LEGAL RIGHTS

TORONTO, March 1, 2024 /CNW/ -

IMPORTANT NOTICE

This is notice of an important development in a proposed class action on behalf of all individuals who were surgical recipients of the ExploR Modular Radial Head System with ExploR Screw which prematurely failed or is in the process of failing or have the Device implanted.

A. Background

The proposed class proceeding filed with the Ontario Superior Court of Justice on January 14, 2022, identified as Koss v Zimmer Biomet Holdings, Inc. et al., Court File No. CV-22-00675252-00CP (the "Koss lawsuit"), will be discontinued effective the date of the order. This order is dated February 16, 2024.

The Koss lawsuit alleges negligence by Zimmer Biomet Holdings Inc., Biomet Orthopedics LLC, Zimmer Biomet Canada Inc., and Zimmer CAS in the design, constructing, manufacturing, inspecting, testing, and marketing of the ExploR Modular Radial Head System with ExploR Screw (trial number 418098, part number 11-210099) used in patient elbow replacement operations and their failure to warn patients and/or surgeons and other healthcare providers of the inherent dangers and risks in using its Device.

The Defendants deny these allegations. 

B. The Proposed Class

The proposed class proceeding advanced claims on behalf of putative class members defined as all persons:

i. who were surgical recipients of the ExploR Modular Radial Head System with ExploR Screw (trial number 418090, part number 11-210099) which prematurely failed or is in the process of failing or has the Device Implanted or, in the alternative, individuals who were surgical recipients of the Device in which the proposed representative Plaintiff had implanted (the "Patient Class"); and

ii. all individuals who are entitled, by virtue of their relationship to a member of the Class, to assert claims pursuant to the Family Law Act and equivalent legislation from other Canadian jurisdictions (the "Family Class").

C. Implications on Limitation Periods

Persons who believe that they come within the defined proposed classes above, SHOULD TAKE NOTICE THAT applicable and remaining limitation periods, if any, for bringing a claim which were "tolled" (i.e. paused) as of January 14, 2022, will resume running 12 months following the date of the order. On the expiry of the limitation period a person's right to sue may be extinguished. Such persons should take notice that the limitation period for bringing a claim, if there is any time left within it, will recommence running on 12 months following the date of the order. If those persons do not commence their own actions within the applicable limitation period(s), then they may be prohibited from pursuing any claims they may have against the Defendants.

D. Action Required

As a result, surgical recipients of the ExploR Modular Radial Head System with ExploR Screw which prematurely failed or is in the process of failing or have the Device implanted wishing to claim compensation should seek legal advice and must commence their individual actions before their respective limitation period(s) expire. Failure to do so may restrict one's ability to pursue a claim for compensation.

E. Contact for Further Information

Do not call the Courthouse with any questions about this Notice. For further information regarding this proposed class proceeding and Notice of Intent to Discontinue, please visit https://www.gluckstein.com/class-actions/zimmer-biomet-explor-modular-radial-head-class-action or contact: 

Jordan D. Assaraf, Gluckstein Lawyers, [email protected], Tel: (416) 408-4252

SOURCE Gluckstein Lawyers


These press releases may also interest you

at 01:00
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on...

at 00:30
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology...

at 00:00
The Riverside Company, a global private investor focused on the smaller end of the middle market, has closed the acquisition of Arbeidsmiljø og Energiteknikk AS (AET), a Norwegian distributor of third-party consumables and laboratory / cleaning...

at 00:00
COEUS Solutions, a leading provider of innovative technologies and services in the life sciences industry, today announces its rebranding to BridgeView Life Sciences ("BridgeView") following a recent spinoff from its former parent company. This marks...

29 avr 2024
General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive...

29 avr 2024
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders.The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction...



News published on and distributed by: